SCHEMBL5394205

SCHEMBL5394205

CC(C)(C)OC(=O)N1CCN(c2ccc(C(F)(F)F)cc2)C(C(=O)O)C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 4/20 0.52
MAPT P10636 2/20 0.51
RORC P51449 1/20 0.45
MCL1 Q07820 1/20 0.45
NOTUM Q6P988 1/20 0.44
TACR1 P25103 1/20 0.42
HDAC6 Q9UBN7 2/20 0.42
CNR2 P34972 2/20 0.41
CYP2C8 P10632 1/20 0.41
CYP2D6 P10635 1/20 0.41
CNR1 P21554 1/20 0.41
CYP2C19 P33261 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
P2RY14 Q15391 1/20 0.41
NR1H2 P55055 1/20 0.41
NR1H3 Q13133 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
CA12 O43570 1/20 0.40
CA2 P00918 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13923464 0.88 MAPT (0.52) GPR119MAPTRORCMCL1TACR1
SCHEMBL5384801 0.88 MEN1 (0.46) GPR119MAPTHDAC6ALDH1A1LMNA
SCHEMBL20142045 0.88 MEN1 (0.46) GPR119MAPTHDAC6ALDH1A1LMNA
SCHEMBL3921237 0.87 GPR119 (0.53) GPR119MAPTRORCNOTUMLMNA
SCHEMBL8236255 0.86 GPR119 (0.55) GPR119RORCUSP30
SCHEMBL21360375 0.86 GPR119 (0.55) GPR119RORCUSP30
SCHEMBL5394170 0.85 GPR119 (0.48) GPR119MAPTRORCTACR1ALDH1A1
SCHEMBL38664257 0.85 GPR119 (0.47) GPR119MAPTALDH1A1LMNAUSP30
SCHEMBL13940334 0.84 GPR119 (0.50) GPR119MAPTRORCTACR1CNR1
SCHEMBL2439382 0.80 MMP1 (0.59) GPR119MAPTMCL1STS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7214680-B2 2-substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors GLAXO GROUP LIMITED (GB) 2007-05-08 US disclosed
US-20040242592-A1 2-Substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors GLAXO GROUP LIMITED (GB) 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242592-A1 2-Substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors SLC6A4, TPH1, HTR1D GPR119 563/4885MAPT 2501/4885RORC 4075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.